Emerging Trends in Exosome Diagnostic and Therapeutic Market: Harnessing the Potential of Extracellular Vesicles for Disease Detection and Treatment

Global exosome diagnostic and therapeutic industry was estimated at $224.34 million in 2020, and is anticipated to hit $2.9 billion by 2030, registering a CAGR of 29.4% from 2021 to 2030.

𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐭:

https://www.alliedmarketresearch.com/request-sample/1723

Exosomes are small extracellular vesicles that are secreted by most cell types and carry various biomolecules, including proteins, lipids, and nucleic acids. Over the past few years, exosomes have emerged as potential diagnostic and therapeutic tools for various diseases.

Exosome Diagnostics:
Exosomes can serve as a non-invasive diagnostic tool for various diseases, including cancer, infectious diseases, and neurological disorders. Exosomes can be isolated from various biological fluids, such as blood, urine, and cerebrospinal fluid, and their contents can be analyzed to detect disease-specific biomarkers.

For example, in cancer, exosomes can carry tumor-specific proteins, nucleic acids, and other molecules that can be used as biomarkers for early diagnosis and monitoring of the disease. In infectious diseases, exosomes can carry pathogen-specific molecules that can be used for diagnosis and monitoring of treatment response. In neurodegenerative diseases, exosomes can carry disease-specific proteins and nucleic acids that can be used for early diagnosis and monitoring of disease progression.

Exosome Therapeutics:
Exosomes can also be used as therapeutic tools for various diseases, including cancer, cardiovascular diseases, and neurological disorders. Exosomes can be engineered to carry therapeutic molecules, such as drugs, proteins, and nucleic acids, and can be targeted to specific cells or tissues.

For example, in cancer, exosomes can be loaded with anti-cancer drugs and targeted to tumor cells to enhance their efficacy and reduce their side effects. In cardiovascular diseases, exosomes can be loaded with growth factors and targeted to damaged tissues to promote tissue regeneration. In neurological disorders, exosomes can be loaded with neuroprotective factors and targeted to damaged neurons to promote neuronal survival and function.

In summary, exosomes have emerged as promising diagnostic and therapeutic tools for various diseases, and ongoing research in this field is expected to lead to new diagnostic and therapeutic strategies in the future.

Alarming rise in prevalence of cancer & infectious disease and increase in number of approval for exosome therapeutics & diagnostics are expected to notably contribute toward the growth of the global exosome diagnostic & therapeutic market during the forecast period.

𝐂𝐨𝐯𝐢𝐝-𝟏𝟗 𝐒𝐜𝐞𝐧𝐚𝐫𝐢𝐨:

Rapid spread of Covid-19 heightened the need for molecular diagnosis, thus impacting the global exosome diagnostic and therapeutic market positively.

This trend is pretty likely to continue till the pandemic is completely over.

COVID-19 positively impacted the exosome diagnostic and therapeutic market share, due to rise in number of infectious disease cases, surge in availability of healthcare services in developing countries, and increase in demand for exosome diagnostic & therapeutic technology. Driving factors of the exosome diagnostic and therapeutic market are improvement in precision and surge in advantages over traditional methods of diagnosis and therapeutics.

𝐄𝐧𝐪𝐮𝐢𝐫𝐲 𝐟𝐨𝐫 𝐒𝐡𝐨𝐫𝐭-𝐭𝐞𝐫𝐦 𝐚𝐧𝐝 𝐋𝐨𝐧𝐠-𝐭𝐞𝐫𝐦 𝐈𝐦𝐩𝐚𝐜𝐭𝐬 𝐨𝐟 𝐂𝐎𝐕𝐈𝐃-𝟏𝟗 𝐚𝐭:

https://www.alliedmarketresearch.com/purchase-enquiry/1723

North America garnered the major share in 2020-

Based on region, North America held the major share in 2020, generating nearly two-fifths of the global exosome diagnostic and therapeutic market, due to rise in product launches for exosome therapeutics, surge in the presence of key players, and development of R&D activities in the pharmaceutical and biopharmaceutical sector across the province. Asia-Pacific, however, would grow at the fastest CAGR of 30.3% by 2030. Increase in the prevalence of chronic and infectious disorders, growth in health care expenditures, and surge in demand for molecular diagnosis drive the market growth in the region.

North America (U.S., Canada, Mexico)

Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)

Asia-Pacific (Japan, China, Rest of Asia-Pacific)

LAMEA (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

𝐖𝐞 𝐎𝐟𝐟𝐞𝐫 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐞𝐝 𝐑𝐞𝐩𝐨𝐫𝐭, 𝐂𝐥𝐢𝐜𝐤 @

https://www.alliedmarketresearch.com/request-for-customization/1723

Key players in the industry-

Exosome Diagnostics Inc.
NanoSomix Inc.
Thermo Fisher Scientific Inc.
Malvern Instruments Ltd.
System Biosciences Inc.
NX Pharmagen
Aethlon Medical, Inc.
Sistemic Inc.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.